Thanks to the editors at Seeking Alpha for publishing my latest:
Dendreon Ready For A Rebound
It is a complex picture, and there are no guarantees. Stocks like Dendreon are best played only by those who are good at balancing risk.
I own Dendreon (DNDN) stock. I have always had some amount of Dendreon since I first bought it in 2004, but sold most of mine in 2009-2010, then started accumulating it again in 2013.
I take notes on Dendreon quarterly results and analyst conferences; follow the link to read them.
Dendreon sells its Provenge therapy for castrate-resistant, minimally symptomatic metastatic prostate cancer.